Shishi Pharmaceutical Group ( 02005.HK ) Net profit for 2025 decreased by 55.6% to HKD 471 million; final dividend of HKD 0.03 per share

Gelonghui, March 27丨Stone Four Pharmaceutical Group (02005.HK) announced its annual performance, achieving a full-year sales revenue of approximately 3.812 billion yuan in 2025, a year-on-year decrease of 27.6%; in Hong Kong dollars, the full-year sales revenue was about 4.165 billion HKD, a year-on-year decrease of 27.8%; the gross profit margin for the same period was approximately 41.6%, a year-on-year decline of 8.8 percentage points; the net profit was approximately 471 million HKD, a year-on-year decrease of 55.6%. The board has resolved to distribute a final dividend of 0.03 HKD per share to shareholders listed on the company’s shareholder register on May 21, 2026, totaling a dividend of 0.08 HKD per share for the year.

In 2025, due to the absence of large-scale epidemics and healthcare cost control in China, the terminal sales volume of pharmaceuticals was affected. In 2025, the overall sales volume of intravenous infusion by the group fell by 24.5% compared to the previous year. Additionally, the expansion of centralized procurement in various forms (including national and local alliance procurement) and the intensifying competition in the domestic and international industries brought continuous price pressure. As a result, the total revenue from intravenous infusion was 2.485 billion HKD, a year-on-year decrease of 33.5%. Among them, the revenue from non-PVC soft bag infusion and upright soft bag infusion was 1.184 billion HKD and 559 million HKD, respectively, totaling 1.743 billion HKD, accounting for 70.1% of total intravenous infusion revenue, a decrease of 36.9% compared to last year; the revenue from polypropylene plastic bottle infusion was 559,268,000 HKD, accounting for 22.5% of total intravenous infusion revenue, a decrease of 29.4% compared to last year; the revenue from glass bottle infusion was 183,559,000 HKD, accounting for 7.4% of total intravenous infusion revenue, an increase of 2.4% compared to last year.

In 2025, the revenue from ampoule injections was 287 million HKD. Although the sales volume of ampoule products increased overall, the revenue decreased by 42.6% compared to last year, mainly due to the decline in the average selling price of ampoule products and the fact that bromhexine hydrochloride injection is no longer sold through national procurement. The revenue from raw materials was 679 million HKD, a decrease of 13.5% compared to last year, due to caffeine sales and market prices not fully recovering from low levels. The revenue from oral formulations was 455 million HKD, a decrease of 9.4% compared to last year, mainly due to the decline in sales of old products, although part of this was offset by the growth in sales of new products.

Massive information and precise interpretation can be found in the Sina Finance APP.